At a glance
- Originator Eisai Co Ltd
- Developer AbbVie
- Class Antineoplastics; Sulfonamides
- Mechanism of Action Dihydropteroate synthase inhibitors; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer; Non-small cell lung cancer; Renal cancer
Most Recent Events
- 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
- 04 Jul 2007 Clinical development is ongoing
- 19 Oct 2004 Data presented at the 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2004) have been added to the Cancer pharmacodynamics section